Common stock
- Symbol
- DARE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Dare Bioscience, Inc.
DARENASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated October 1, 2026, which is incorporated herein by reference. The Company intends to use the presentation and its contents in various meetings with securities market participants and others, commencing on October 1, 2026.…
Company context
We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.
Current securities
Registered securities in this filing
Dare Bioscience, Inc · 8-K · Filed 2026-10-01
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
Furnished
as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the
“Company”) dated October 1, 2026, which is incorporated herein by reference. The Company intends to use the presentation
and its contents in various meetings with securities market participants and others, commencing on October 1, 2026.
The
Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com),
on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained
in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated
by reference into this report.
The
information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange
Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation
by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1
Open exhibit ↗